He obtained a masters degree in Clinical & Translational Science from the University of Connecticut. His work has been funded by the American Cancer Society, American Urological Association, American Geriatrics Society, NIH/NCI and the DOD.
He was instrumental in developing the Foundation from its inception in 1979 to its role in scientific research, workshops and publications.
Dr. Molly Ingersoll is currently a Research Director with joint appointment between Institut Cochin and Institut Pasteur in Paris. Her team studies mucosal immunity in the bladder in the context of infection and …..
cancer to understand how this tissue responds to infectious and non-infection inflammatory diseases and to develop immunomodulatory approaches to improve disease outcomes. Dr. Ingersoll received her PhD studying host-pathogen interactions from NYU School of Medicine working with Arturo Zychlinsky at NYU and at the Max Planck Institute for Infection Biology in Berlin, Germany. A brief postdoctoral fellowship at Washington University School of Medicine, in St Louis, MO with Scott Hultgren, studying innate immunity to urinary tract infection was followed by a postdoctoral appointment at Mount Sinai Medical Center in NYC, investigating monocyte and dendritic cell biology. She started her independent career, moving to Paris, in 2012.
Dr. Konety has held various other leadership positions in the past including serving as the Chief Executive Officer University of Minnesota Physicians, Vice Dean for Clinical Affairs University of Minnesota and Chief Clinical Officer for MHealth Fairview. A distinguished professor, Dr. Konety was Chair of the Department of Urology, U of Minnesota for more than a decade. He had multiple leadership positions during his tenure at the University of Minnesota (Associate Dean for Innovation and Director of the Institute for Prostate and Urologic Cancers, Associate Director for Clinical Affairs at the Masonic Cancer Center, Chair Oncology Service Line Steering committee and Chair Finance Committee).
Dr. Konety completed his residency, MBA and American Foundation for Urologic Disease Research Scholar fellowship at the University of Pittsburgh. He completed his urologic oncology fellowship at Memorial Sloan Kettering Cancer Center.
An accomplished clinician, researcher and scholar, Dr. Konety has authored or co-authored over 350 peer reviewed publications, numerous book chapters and edited two books. He has been and is principal or co-investigator on grants funded through the Department of Defense, National Institutes of Health, American Geriatrics Society, and Center for Disease Control. He has participated in many multi-institutional clinical trials.
Dr. Konety’s research work has focused on both basic science and outcomes/health services research. He has worked on developing new strategies for gene therapy using Ad5PSA and Ad5Trail for advanced prostate cancer with studies being translated from the lab to phase I clinical trials. He has also been involved in preclinical studies of novel chemotherapeutic agents (lupeol) for the prevention as well as inhibition of prostate cancer growth. He has worked with collaborators on new markers for aggressive prostate cancer such as ROBO1 and S100A4. He has also been involved in developing new markers for bladder cancer. He has also led projects that focus on outcomes, cost effectiveness and quality of life in patients with bladder and prostate cancer. He has been the co lead and co-founder of CHAAMPS which is a national center conducting research on African American Men’s Health. He is also a collaborative investigator on RESTORE, a series of NIH funded studies on prostate cancer in sexual minority men. He has been involved in several clinical trials for a variety of diagnostic and therapeutic interventions for bladder cancer and has served on guideline committees for bladder and prostate cancer. He has been involved in founding and developing start-up companies and one of them (Astrin Biosciences) has developed a novel blood based test for breast cancer that has recently been commercialized while tests on prostate and other cancers are in development.
Dr. Konety is an active member of numerous professional medical societies including the American Urological Association, the American College of Surgeons, Societe Internationale D’Urologie (SIU) and the American Association of Genitourinary Surgeons. He is the former President of the SIU, the Society of Academic Urology and the Minnesota Urologic Society. He has been the Associate Editor of the Journal of Urology. He is also a member of several other editorial boards and the executive leadership of several societies. He has received the Jahnigen Career Development Scholar Award (American Geriatric Society), the Ferdinand Valentine fellowship (New York Academy of Medicine) the David Utz award (Minnesota Urologic Society) and the Felix Guyon Medal (SIU). He was also recognized by election as a Fellow of the Royal College of Physicians and Surgeons of Glasgow. He has trained and mentored scores of students, residents and fellows.
The SAB includes respected members of the bladder cancer community to include; genitourinary oncologists, urologic oncologists and basic scientists with focus on bladder cancer. The SAB is responsible for directing the scientific content of the annual symposium, appointing the annual symposium steering committee, and reviewing competitive applications for potential funding and Albert Institute summer fellow positions.
He serves as a Program Leader for the Cancer Therapeutics Program and Co-Director of the Urologic Oncology Program at the UNC Lineberger Comprehensive Cancer Center. Dr. Milowsky is a medical oncologist and clinical and translational researcher. His clinical interest is in
the treatment of patients with genitourinary cancers with a focus on the care of patients
with advanced bladder cancer. His research involves the development of novel therapies for patients with urologic cancers with a particular interest in the design of clinical trials that utilize immunotherapy as well as those that use an integrated genomics approach to characterize urothelial cancers for genetic alterations that may represent targets for novel agents.
and the Co-Medical Director of the Urologic-Oncology Clinic at the Anschutz Cancer Pavilion.
Dr. Kessler is a recognized clinical expert in GU medical oncology and is an active clinical researcher serving as the local principal investigator on many phase I, II, and III trials as well as many investigator initiated trials. Her research program focuses on using implementation science methods to improve the delivery of goal aligned care to older adults with advanced cancer. She has received funding from the DOD, ACS, ASCO and NIH.
He has received multiple awards for his research in urothelial carcinoma and has an active interest in the molecular mechanisms driving response and resistance to immune-based therapies in bladder and kidney cancer. Dr. Alam completed his Urology residency at the University of Kansas and his Urologic Oncology fellowship at Memorial Sloan-Kettering Cancer Center.
Dr. Woolbright earned his Ph.D. from Kansas University Medical Center working on metabolism and disposition of bile acids. He subsequently completed a postdoctoral fellowship in liver disease before shifting his focus to bladder cancer.
His primary research is now on interactions between aging, the microbiome and the role of inflammation in bladder cancer treatment and development and the development of therapeutic agents aimed at treating and preventing bladder cancer in human patients.
